BERTINARIA, Massimo
BERTINARIA, Massimo
SCIENZA E TECNOLOGIA DEL FARMACO
A multitarget approach to optimize the safety profile of coxibs: lumiracoxib derivatives with dual cyclooxygenase-2 inhibitor-thromboxane A2 receptor antagonist activity
2013-01-01 Malvina Hoxha; Valerie Capra; Carola Buccellati; Angelo Sala; Mohammed Abrar Abdul Gaffar Shaikh; Clara Cena; Roberta Fruttero; Alberto Gasco; G. Enrico Rovati; Massimo Bertinaria
Carnosine analogues containing Phenol substructures
2012-01-01 Giorgis M.; Bertinaria M.; Rolando B.; Montanaro G.; Fruttero R.; Gasco A.
Design and synthesis of encorafenib-based BRAF-V600E degraders
2022-01-01 Federica Blua, Marco Marino, Simone Gastaldi, Federica Maione, Eleonora Gianquinto, Federica Di Nicolantonio, Massimo Bertinaria
Design and synthesis of INF195, a new NLRP3 Inflammasome Inhibitor with ex vivo cardioprotective effect
2024-01-01 Francesca Boccato, Simone Gastaldi, Magalì Giordano, Elisabetta Marini, Francesca Spyrakis, Pasquale Pagliaro, Claudia Penna, Massimo Bertinaria
Design and synthesis of SWIR emitters for optical imaging
2022-01-01 Federica Blua, Mariangela Boccalon, Barbara Rolando, Roberta Napolitano, Massimo Bertinaria
Design, Synthesis and Pharmacological Evaluation of Anti-Pyroptotic Compounds Acting on NLRP3 Inflammasome Signaling Pathway: a New Start for Anti-Inflammatory Drugs?
2014-01-01 Bertinaria Massimo; Cocco Mattia; Garella Davide; Marini Elisabetta; Di Stilo Antonella; Miglio Gianluca
Design, synthesis and selection of INF200, a new non-sulfonylurea based NLRP3 inhibitor
2023-01-01 Federica Blua, Eleonora Gianquinto, Maria Concetta Granieri, Valentina Boscaro, Massimo Bertinaria
Different multitarget approaches to manage coxibs associatedcardiovascular risk. Design and synthesis of new lumiracoxibderivatives
2012-01-01 M. Bertinaria; M. A. A. G. Shaikh; C. Cena; B. Rolando; L. Lazzarato; R. Fruttero; A. Gasco; G. E. Rovati; C. Buccellati; V. Capra; A. Sala
Do P2Y12 receptor antagonism and NLRP3 inhibition exert additive cardioprotective effects against ischemia/reperfusion injury?
2019-01-01 Fausto Chiazza, Saveria Femminò, Debora Collotta, Elisa Zicola, Manuela Aragno, Massimo Bertinaria, Pasquale Pagliaro, Claudia Penna, Massimo Collino
EVALUATION OF THE ANTIPYROPTOTIC ACTIVITY OF NEW INFLAMMASOME INHIBITORS
2021-01-01 Boscaro Valentina, Gastaldi Simone, Bertinaria Massimo, Gallicchio Margherita
EXPLORING THE AMYLOID BETA (ABETA) DEPENDENT METABOLIC FINGERPRINT OF HIPPOCAMPAL NEURONS BY TWO-DIMENSIONAL COMPREHENSIVE GAS CHROMATOGRAPHY: POTENTIALS IN DRUG DISCOVERY STUDIES
2014-01-01 Davide Bressanello; Davide Garella; Massimo Bertinaria; Andrea Marcantoni; Claudio Franchino; Gianluca Miglio; Stephen E. Reichenbach; Carlo Bicchi; Chiara Cordero
H3 Receptor Ligands: New Imidazole H3-antagonists Endowed with NO-Donor Properties
2002-01-01 M. BERTINARIA
Identification of Small Synthetic Anti-Pyroptotic Compounds
2013-01-01 G. Miglio; M. Bertinaria; M. Rogazzo; M. Cocco; D. Garella; A. Di Stilo; R. Fantozzi
In silico study of NLRP3: towards selective inhibition with small molecules
2019-01-01 Alejandro Gómez García, Simone Gastaldi, Giulia Fumero, Massimo Bertinaria, José Luis Medina Franco
In the search for new NLRP3 inhibitors: chemical modulation of the 1-(piperidin-4-yl)-1,3-dihydro-2 Hbenzo[d]imidazole-2-one scaffold
2021-01-01 Simone Gastaldi, Valentina Boscaro, Eleonora Gianquinto, Christina F. Sandall, Marta Giorgis, Elisabetta Marini, Federica Blua, Margherita Gallicchio, Francesca Spyrakis, Justin A. MacDonald, Massimo Bertinaria
Inhibition of NLRP3 ATPase activity: a new strategy to fight chronic inflammatory diseases
2019-01-01 Simone Gastaldi, Federica Blua, Marta Giorgis, Elisabetta Marini, Massimo Bertinaria
Is NLRP3 inflammasome a new pharmacological target in myocardial ischemia/reperfusion injury?
2015-01-01 Femminò, S; Chiazza, F; Mastrocola, R; Tullio, F; Penna, C; Nigro, D; Alloatti, G; Cocco, M; Garella, D; Bertinaria, M; Fantozzi, R; Aragno, M; Collino, M; Pagliaro, P
NEW NON-COVALENT INHIBITORS OF NLRP3 INFLAMMASOME ATPASE ACTIVITY
2019-01-01 Gastaldi, S; Marino, M.; Giorgis, M.; Marini, E.; Boscaro, V.; Gallicchio, M.; Bertinaria, M.
New non-sulfonylurea NLRP3 inhibitors: discovery and selection of INF200, a 1,3,4-oxadiazol-2-one-based NLRP3 inhibitor
2024-01-01 Alberto Gasparotto, Federica Blua, Maria Concetta Granieri, Eleonora Gianquinto, Valentina Boscaro, Massimo Bertinaria
New tools for the development of direct NLRP3 inflammasome inhibitors
2018-01-01 Elisabetta Marini, Marta Giorgis, Massimo Bertinaria
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A multitarget approach to optimize the safety profile of coxibs: lumiracoxib derivatives with dual cyclooxygenase-2 inhibitor-thromboxane A2 receptor antagonist activity | 2013 | Malvina Hoxha; Valerie Capra; Carola Buccellati; Angelo Sala; Mohammed Abrar Abdul Gaffar Shaikh; Clara Cena; Roberta Fruttero; Alberto Gasco; G. Enrico Rovati; Massimo Bertinaria | |
| Carnosine analogues containing Phenol substructures | 2012 | Giorgis M.; Bertinaria M.; Rolando B.; Montanaro G.; Fruttero R.; Gasco A. | |
| Design and synthesis of encorafenib-based BRAF-V600E degraders | 2022 | Federica Blua, Marco Marino, Simone Gastaldi, Federica Maione, Eleonora Gianquinto, Federica Di Nicolantonio, Massimo Bertinaria | |
| Design and synthesis of INF195, a new NLRP3 Inflammasome Inhibitor with ex vivo cardioprotective effect | 2024 | Francesca Boccato, Simone Gastaldi, Magalì Giordano, Elisabetta Marini, Francesca Spyrakis, Pasquale Pagliaro, Claudia Penna, Massimo Bertinaria | |
| Design and synthesis of SWIR emitters for optical imaging | 2022 | Federica Blua, Mariangela Boccalon, Barbara Rolando, Roberta Napolitano, Massimo Bertinaria | |
| Design, Synthesis and Pharmacological Evaluation of Anti-Pyroptotic Compounds Acting on NLRP3 Inflammasome Signaling Pathway: a New Start for Anti-Inflammatory Drugs? | 2014 | Bertinaria Massimo; Cocco Mattia; Garella Davide; Marini Elisabetta; Di Stilo Antonella; Miglio Gianluca | |
| Design, synthesis and selection of INF200, a new non-sulfonylurea based NLRP3 inhibitor | 2023 | Federica Blua, Eleonora Gianquinto, Maria Concetta Granieri, Valentina Boscaro, Massimo Bertinaria | |
| Different multitarget approaches to manage coxibs associatedcardiovascular risk. Design and synthesis of new lumiracoxibderivatives | 2012 | M. Bertinaria; M. A. A. G. Shaikh; C. Cena; B. Rolando; L. Lazzarato; R. Fruttero; A. Gasco; G. E. Rovati; C. Buccellati; V. Capra; A. Sala | |
| Do P2Y12 receptor antagonism and NLRP3 inhibition exert additive cardioprotective effects against ischemia/reperfusion injury? | 2019 | Fausto Chiazza, Saveria Femminò, Debora Collotta, Elisa Zicola, Manuela Aragno, Massimo Bertinaria, Pasquale Pagliaro, Claudia Penna, Massimo Collino | |
| EVALUATION OF THE ANTIPYROPTOTIC ACTIVITY OF NEW INFLAMMASOME INHIBITORS | 2021 | Boscaro Valentina, Gastaldi Simone, Bertinaria Massimo, Gallicchio Margherita | |
| EXPLORING THE AMYLOID BETA (ABETA) DEPENDENT METABOLIC FINGERPRINT OF HIPPOCAMPAL NEURONS BY TWO-DIMENSIONAL COMPREHENSIVE GAS CHROMATOGRAPHY: POTENTIALS IN DRUG DISCOVERY STUDIES | 2014 | Davide Bressanello; Davide Garella; Massimo Bertinaria; Andrea Marcantoni; Claudio Franchino; Gianluca Miglio; Stephen E. Reichenbach; Carlo Bicchi; Chiara Cordero | |
| H3 Receptor Ligands: New Imidazole H3-antagonists Endowed with NO-Donor Properties | 2002 | M. BERTINARIA | |
| Identification of Small Synthetic Anti-Pyroptotic Compounds | 2013 | G. Miglio; M. Bertinaria; M. Rogazzo; M. Cocco; D. Garella; A. Di Stilo; R. Fantozzi | |
| In silico study of NLRP3: towards selective inhibition with small molecules | 2019 | Alejandro Gómez García, Simone Gastaldi, Giulia Fumero, Massimo Bertinaria, José Luis Medina Franco | |
| In the search for new NLRP3 inhibitors: chemical modulation of the 1-(piperidin-4-yl)-1,3-dihydro-2 Hbenzo[d]imidazole-2-one scaffold | 2021 | Simone Gastaldi, Valentina Boscaro, Eleonora Gianquinto, Christina F. Sandall, Marta Giorgis, Elisabetta Marini, Federica Blua, Margherita Gallicchio, Francesca Spyrakis, Justin A. MacDonald, Massimo Bertinaria | |
| Inhibition of NLRP3 ATPase activity: a new strategy to fight chronic inflammatory diseases | 2019 | Simone Gastaldi, Federica Blua, Marta Giorgis, Elisabetta Marini, Massimo Bertinaria | |
| Is NLRP3 inflammasome a new pharmacological target in myocardial ischemia/reperfusion injury? | 2015 | Femminò, S; Chiazza, F; Mastrocola, R; Tullio, F; Penna, C; Nigro, D; Alloatti, G; Cocco, M; Garella, D; Bertinaria, M; Fantozzi, R; Aragno, M; Collino, M; Pagliaro, P | |
| NEW NON-COVALENT INHIBITORS OF NLRP3 INFLAMMASOME ATPASE ACTIVITY | 2019 | Gastaldi, S; Marino, M.; Giorgis, M.; Marini, E.; Boscaro, V.; Gallicchio, M.; Bertinaria, M. | |
| New non-sulfonylurea NLRP3 inhibitors: discovery and selection of INF200, a 1,3,4-oxadiazol-2-one-based NLRP3 inhibitor | 2024 | Alberto Gasparotto, Federica Blua, Maria Concetta Granieri, Eleonora Gianquinto, Valentina Boscaro, Massimo Bertinaria | |
| New tools for the development of direct NLRP3 inflammasome inhibitors | 2018 | Elisabetta Marini, Marta Giorgis, Massimo Bertinaria |